Gomekli Approved for Patients With Neurofibromatosis Type 1

The FDA has approved Gomekli, a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.